Abstract 240P
Background
Small intestinal cancer constitutes approximately 4% of all gastrointestinal tumors. It presents diverse histologic subtypes, including neuroendocrine tumors (NETs) and adenocarcinomas. Understanding trends in subtype-specific incidence rates (IRs) over time is crucial for effective management. Limited research exists on the variations in IRs among different histological subtypes and anatomical sites, leaving a gap in understanding of disease progression and nature. Thus, this study aimed to analyze the incidence rates of small intestinal cancer subtypes over time and evaluate the factors contributing to the observed trends.
Methods
Data on patients diagnosed with small intestinal cancer from 2000 to 2020 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence Rates (IRs) were calculated per 100,000 population for average three years, age-adjusted to the 2000 US Standard Population. Trends were analyzed as percent change (PC) and Annual Percent Change (APC) with 95% Confidence Interval (CI), considering results significant P<0.05.
Results
Small intestinal cancer demonstrated an increasing trends from 2000 to 2020, with PC of 53.5 and an APC of 2.0% (95% CI: 1.7-2.2, P < 0.05). Duodenal cancer showed a PC of 59.6 and a significant APC of 2.2% (95% CI: 1.8-2.6, P< 0.05) while jejunal cancer had an APC of 1.2% (95% CI: 0.4-1.9, P< 0.05) and ileal cancer had an APC of 2.0% (95% CI: 1.6-2.4, P< 0.05). Overlapping lesions of the small intestine displayed had a PC of 24.4 and an APC of -0.1% (95% CI: -1.5-1.3, P < 0.05). For small intestinal cancer, the 3-year average annual IR was +1.6 (1.3-1.9 per 100 000) and the steepest increase was observed in the duodenum +75% (0.6- 0.9 per 100 000). Neuroendocrine tumors had 3-year average annual IR of +85% (0.6- 1.1 per 100 000).
Conclusions
The analysis reveals a significant increasing trends and annual IRs of small intestinal cancer over the past two decades especially neuroendocrine tumors of the small intestine which is an alarming sign to encourage clinical practice and public health strategies to implement regular screening programs for prevention, early detection, and management of this rare and potentially lethal malignancy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.